Fed’s Barkin: Strained Consumer Finances Weaken Tariff-Driven Inflation Effects
According to a report by Jinse Finance, the Wall Street Journal cited Federal Reserve official Thomas Barkin as saying that there are currently numerous signs indicating that middle- and low-income consumers are feeling more financially strained than a few years ago. This could dampen their spending, thereby mitigating the inflationary impact of tariffs. “The theory that tariff costs will inevitably be passed on to consumers and cause a surge in inflation must be tested against how consumers actually respond,” he stated. “I believe consumers will accept price increases for certain essential goods, but they will inevitably resist higher prices in other areas by trading down or delaying purchases.” Speaking about the inflation outlook, Barkin noted, “We will see some inflation, but it will be milder than expected, because this is no longer 2022—when consumers had ample cash and a strong willingness to spend. The reality in 2025 is that consumers are feeling financially squeezed and therefore have to be more frugal.”
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy
Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized
BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review
Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).
4 Big Bank Earnings to Watch This Week as Wall Street Turns Bullish
